Ex­clu­sive: GSK re­vamps its re­search strat­e­gy, build­ing three teams to tar­get spe­cif­ic dis­ease spaces

GSK is shak­ing up the way it does re­search and cre­at­ed three unique teams ze­ro­ing in on vac­cines and in­fec­tious dis­eases, res­pi­ra­to­ry and im­munol­o­gy, and on­col­o­gy. The changes went live Mon­day.

Kaivan Kha­van­di is re­join­ing GSK from Benev­o­len­tAI to lead the res­pi­ra­to­ry and im­munol­o­gy re­search team. Phil Dor­mitzer, GSK’s se­nior vice pres­i­dent and glob­al head of vac­cines R&D, will broad­en his re­mit by al­so cov­er­ing in­fec­tious dis­eases. And GSK’s se­nior vice pres­i­dent glob­al head for on­col­o­gy de­vel­op­ment, He­s­ham Ab­dul­lah, will stay on as the on­col­o­gy lead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER